Ignite Creation Date:
2025-12-24 @ 3:22 PM
Ignite Modification Date:
2026-01-28 @ 8:52 PM
Study NCT ID:
NCT06840392
Status:
RECRUITING
Last Update Posted:
2025-10-31
First Post:
2025-02-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Hidradenitis Suppurativa | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Hidradenitis Suppurativa clinical response | View |
| None | Bruton's tyrosine kinase (BTK) inhibitor | View |
| None | Hidradenitis Suppurativa | View |
| None | HS | View |
| None | HiSCR | View |
| None | remibrutinib | View |
| None | LOU064 | View |
| None | Hidradenitides, Suppurativa | View |
| None | Hidradenitis, Suppurativa | View |
| None | Suppurativa Hidradenitides | View |
| None | Suppurativa Hidradenitis | View |
| None | Acne inversa, | View |
| None | Verneuil disease | View |
| None | Inflammatory skin disease | View |
| None | Chronic skin condition | View |